Among patients with NSCLC and the TP53 and ATM comutation, 8.1% of patients in the TCGA cohort15 and 7.7% of patients in the Geneplus cohort also had anaplastic lymphoma kinase (ALK) tyrosine kinase receptor (OMIM 105590) fusion (Figure 1B). Here, ALK is linked to non-small cell lung carcinoma.